Basic Information | Overview of PTM Sites | Experimental PTM Sites | Protein-Protein Interactions | Drug and Disease Associations | Related Literatures
Basic Information
Protein Name :  Mineralocorticoid receptor  

UniProtKB / Swiss-Prot ID :  MCR_HUMAN

Gene Name (Synonyms) : 
NR3C2, MCR, MLR  

Species :  Homo sapiens (Human). 

Subcellular Localization :  Cytoplasm. Nucleus. Endoplasmic reticulum membrane; Peripheral membrane protein. Note=Cytoplasmic and nuclear in the absence of ligand; nuclear after ligand-binding. When bound to HSD11B2, it is found associated with the endoplasmic reticulum membrane. 

Protein Function :  Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels. 

Protein Sequence METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQEL...
Predicted Secondary Structure CCCCCCCCCCCCCCHHHHHHHHHHHHHHCCCCCCCCCCCCCEEEEEEEEEECCCCCCCCCCCCCHHHHHH...
Protein Variant
LocationDescription
7H -> Q (in a colorectal cancer sample;somatic mutation).
180I -> V (high frequency in healthyindividuals; found in a patient with
241A -> V (high frequency in healthyindividuals; found in a patient with
444N -> T (in dbSNP:rs5523). VAR_014624
537R -> Q (in dbSNP:rs5526). VAR_014625
554N -> S (in dbSNP:rs5527). VAR_014626
633G -> R (in AD-PHA1; reduces transcriptiontransactivation upon aldosterone
645C -> S (in AD-PHA1). VAR_031269
659R -> S (in AD-PHA1). VAR_031270
759P -> S (in AD-PHA1). VAR_031271
769L -> P (in AD-PHA1). VAR_031272
770N -> K (in AD-PHA1). VAR_031273
776Q -> R (in AD-PHA1; reduces aldosteronebinding).
805S -> P (in AD-PHA1). VAR_031275
810S -> L (in EOHSEP; alters receptorspecificity and leads to constitutive
815S -> R (in AD-PHA1). VAR_031276
818S -> L (in AD-PHA1; abolishestranslocation to the nucleus and
826F -> Y (in dbSNP:rs13306592). VAR_029311
924L -> P (in AD-PHA1; abolishestranscription transactivation upon
972E -> G (in AD-PHA1; reduces affinity foraldosterone and transcription
979L -> P (in AD-PHA1; loss of aldosteronebinding and transcription
- top -

Overview of Protein Modification Sites with Functional and Structural Information
Accessible Surface Area (ASA)
Pred. Secondary
Real Secondary
Disorder Prediction
Protein Domain
&
Experimental PTM Sites
Predicted PTM Sites
Protein Variant
- top -

Experimental Post-Translational Modification Sites Download
Locations
Modification
Substrate Sites
&
Secondary Structure
Accessible Surface Area (%)
Resource
Reference
Structural Characterization
Orthologous
Protein Cluster
8PhosphoserineKGYHSLPEG
CCCCCCCCC
36.82Phosphositeplus
Link-
129PhosphoserineQGSMSPAKI
HCCCCHHHH
24.33Phosphositeplus
Link-
168PhosphoserineFMSDSGSSV
HCCCCCCCC
33.01Phosphositeplus
Link-
183PhosphoserineAIVKSPIMC
HHHHCCCEE
14.57Phosphositeplus
Link-
196PhosphoserinePSVCSPLNM
CCCCCCCCC
30.21Phosphositeplus
Link-
227PhosphoserineFPVHSPITQ
CCCCCCCCC
20.45Phosphositeplus
Link-
238PhosphoserinePLTCSPNAE
CCCCCCCCC
18.89Phosphositeplus
Link-
250PhosphoserineSRSHSPAHA
CCCCCCCCH
25.65Phosphositeplus
Link-
255PhosphoserinePAHASNVGS
CCCHHCCCC
23.37Phosphositeplus
Link-
259PhosphoserineSNVGSPLSS
HCCCCCCCC
20.56Phosphositeplus
Link-
262PhosphoserineGSPLSSPLS
CCCCCCCCC
33.04Phosphositeplus
Link-
263PhosphoserineSPLSSPLSS
CCCCCCCCC
37.23Phosphositeplus
Link-
274PhosphoserineSSISSPPSH
CCCCCCCCC
38.88Phosphositeplus
Link-
283PhosphoserineCSVKSPVSS
CCCCCCCCC
28.51Phosphositeplus
Link-
287PhosphoserineSPVSSPNNV
CCCCCCCCC
31.70Phosphositeplus
Link-
299PhosphoserineSSVSSPANI
CCCCCHHHH
26.35Phosphositeplus
Link-
311PhosphoserineRCSVSSPSN
CCCCCCCCC
21.90Phosphositeplus
Link-
361PhosphoserineDVVPSPDTQ
CCCCCCCCC
24.65Phosphositeplus
Link-
424PhosphoserineDSSFSVPIK
CCCCCCCCC
29.00Phosphositeplus
Link-
543PhosphoserineARDQSFQHL
CCCCCCCCC
31.03Phosphositeplus
Link-
735PhosphothreonineSRALTPSPV
HHHHHHHHH
22.27Phosphositeplus
Link-
737PhosphoserineALTPSPVMV
HHHHHHHHH
25.54Phosphositeplus
Link
843PhosphoserineKMHQSAMYE
HHHHHHHHH
10.58Phosphositeplus
Link
- top -

Protein-Protein Interactions
      Interacting Protein      
Interaction type
Source ID
      Resource      
      Pubmed ID      
Domain-Domain Interactions
ACTG_HUMANin vitroHPRD:02991HPRD8612804
ACTS_HUMANin vitroHPRD:02991HPRD8612804
GCR_HUMANin vitro
in vivo
HPRD:02991HPRD11154266
HS90A_HUMANin vitroHPRD:02991HPRD9392437
PIAS3_HUMANin vitro
in vivo
yeast 2-hybrid
HPRD:02991HPRD15171715
TIF1A_HUMANin vitroHPRD:02991HPRD9115274
11518808
- top -

Disease Reference
Kegg disease
H00243 Hyperkalemic distal renal tubular acidosis (RTA type 4), including: Pseudohypoaldosteronism type I
H00603 Hypertension exacerbated in pregnancy
OMIM disease
177735Pseudohypoaldosteronism 1, autosomal dominant (PHA1A)
605115Early-onset hypertension with severe exacerbation in pregnancy (EOHSEP)
Drug Reference
Kegg drug
D00443 Spironolactone (JP16/USP/INN); Aldactone (TN)
D01115 Eplerenone (JAN/USAN/INN); Inspra (TN)
D01943 Potassium canrenoate (JP16); Canrenoate potassium (USAN); Soldactone (TN)
D03363 Canrenone (USAN)
D03698 Desoxycorticosterone acetate (USP); Doca (TN)
D03699 Desoxycorticosterone pivalate (USP); Percorten (TN)
D03792 Dicirenone (USAN)
D03917 Drospirenone (JAN/USP/INN)
D05020 Mexrenoate potassium (USAN); Mexrenoate potassium dihydrate
D05640 Prorenoate potassium (USAN/INN)
D07792 Desoxycortone (INN); Desoxycorticosterone
DrugBank
DB01395Drospirenone
DB00700Eplerenone
DB01023Felodipine
DB00687Fludrocortisone
DB00588Fluticasone Propionate
DB00393Nimodipine
DB00396Progesterone
DB00421Spironolactone
- top -
Related Literatures of Post-Translational Modification
- top -
Basic Information | Overview of PTM Sites | Experimental PTM Sites | Protein-Protein Interactions | Drug and Disease Associations | Related Literatures